# US 2003/0229209 A1 · Extracellular signal-regulated kinase sequences and methods of production and use

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0229209 A1
- Document ID: US20030229209A1
- Status: Published application
- Kind: A1
- Application number: 10/461,402
- Filed: 2003-06-16
- Published: 2003-12-11
- Earliest claimed: 1993-03-19
- Assignees: Max-Planck-Gesellschaft zur Forderung der Wissenschaften
- Inventors: Cornelia Lechner; Niels Peter Moller; Axel Ullrich
- Web page: https://patentgrep.com/patent/US20030229209A1

## CPC

- C07K 16/40: against enzymes
- A61P 3/08: for glucose homeostasis (pancreatic hormones A61P5/48)
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C12N 9/12: transferring phosphorus containing groups, e.g. kinases (2.7)
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- A61K 48/00: Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- C07K 2319/00: Fusion polypeptide
- C12N 2799/021: for the expression of a heterologous nucleic acid
- Y10S 530/809: Fused cells, e.g. hybridoma
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- Y10S: TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS

## Abstract

The present invention relates, in general, to an extracellular signal regulated kinase, ERK-5. In particular, the present invention relates to nucleic acid molecules coding for ERK-5; ERK-5 polypeptides; recombinant nucleic acid molecules; cells containing the recombinant nucleic acid molecules; antisense ERK-5 nucleic acid constructs; antibodies having binding affinity to an ERK-5 polypeptide; hybridomes containing the antibodies; nucleic acid probes for the detecting of ERK-5 nucleic acid; a method of detecting ERK-5 nucleic acid or polypeptide in a sample; kits containing nucleic acid probes or antibodies; a method of detecting a compound capable of binding to ERK-5 or a fragment thereof; a method of detecting an agonist or antagonist of ERK-5 activity; a method of agonizing or antagonizing ERK-5 associated activity in a mammal; a method of treating diabetes mellitus, skeletal muscle diseases, Alzheimer's disease, or peripheral neuropathies in a mammal with an agonist or antagonist of ERK-5 activity; and a pharmaceutical composition comprising an ERK-5 agonist or antagonist.

## Claims

### Claim 1

An isolated, enriched or purified polypeptide comprising an amino acid sequence corresponding to at least 9 contiguous amino acids of SEQ. ID. NO. 2.

### Claim 2 (depends on 1)

The isolated, enriched, or purified polypeptide of claim 1, wherein the polypeptide has an amino acid sequence corresponding to at least 13 contiguous amino acids of SEQ ID NO: 2.

### Claim 3 (depends on 2)

The isolated, enriched, or purified polypeptide of claim 2, wherein the polypeptide has an amino acid sequence corresponding to at least 25 contiguous amino acids of SEQ ID NO: 2.

### Claim 4

An organism or cell that contains a recombinant nucleic acid molecule comprising, 5′ to 3′, a promoter effective to initiate transcription in a host cell and a nucleic acid sequence encoding at least 9 contiguous amino acids of SEQ. ID. NO. 2.

### Claim 5

An organism or cell that contains a recombinant nucleic acid molecule comprising a transcriptional region functional in a cell, a sequence complimentary to an RNA sequence encoding at least 9 amino acids of SEQ. ID. NO. 2, and a transcriptional termination region functional in said cell.

### Claim 6

An antibody having a detectably stronger binding affinity to a polypeptide comprising at least 9 contiguous amino acids of SEQ. ID. NO. 2, than to a polypeptide comprising 9 or more contiguous amino acids of ERK-1, ERK-2, ERK-3, or ERK-4.

### Claim 7 (depends on 6)

The antibody of claim 6, wherein said antibody is a monoclonal antibody.

### Claim 8 (depends on 6)

A method of detecting the presence or amount of a polypeptide comprising at least 9 contiguous amino acids of SEQ. ID. NO. 2 in a sample, comprising:
a) contacting'said sample with an antibody of claim 6, under conditions such that immunocomplexes form, and
b) detecting the presence or amount of said antibody bound to said polypeptide.

### Claim 9 (depends on 6)

A diagnostic kit comprising:
i) a first container means containing the antibody according to claim 6, and
ii) second container means containing a conjugate comprising a binding partner of said monoclonal antibody and a label.

### Claim 10 (depends on 6)

A hybridoma which produces the monoclonal antibody according to claim 6.

### Claim 11

A method of detecting a compound capable of binding to a polypeptide comprising at least 9 contiguous amino acids of SEQ. ID. NO. 2 comprising the steps of incubating the compound with said polypeptide and detecting the presence of the compound bound to said polypeptide.

### Claim 12

A method of detecting an agonist or antagonist of ERK-5 activity comprising incubating cells that produce ERK-5 in the presence of a compound and detecting changes in the level of ERK-5 activity.

### Claim 13

A method of agonizing or antagonizing ERK-5 associated activity in a mammal comprising administering to said mammal an agonist or antagonist to ERK-5 in an amount sufficient to effect said agonism or antagonism.

### Claim 14 (depends on 13)

The method of claim 13 wherein said mammal has a muscle cell differentiation disorder.

### Claim 15

A pharmaceutical composition comprising an ERK-5 agonist or antagonist in an amount sufficient to alter ERK-5 associated activity, and a pharmaceutically acceptable diluent, carrier, or excipient.

### Claim 16

A method of screening for an agent useful in treating a disorder characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway involves the interaction between ERK-5 and an ERK-5 binding partner, comprising the step of assaying potential agents for those able to disrupt or promote said interaction as an indication of a useful said agent.

### Claim 17

A method of diagnosing a disorder characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway involved the interaction between ERK-5 and an ERK-5 binding partner, comprising the step of detecting the level of said interaction as an indication of said disorder.

### Claim 18

A method of treating a disorder characterized by an abnormality in a signal transduction pathway, wherein said signal transduction pathway involved the interaction between ERK-5 and an ERK-5 binding partner, comprising the step of disrupting or promoting said interaction in vivo.

### Claim 19 (depends on 20)

The method of claim 20 wherein said disorder is a muscle cell differentiation disorder.

### Claim 20 (depends on 21)

The method of claim 21 wherein said muscle cell differentiation disorder is a muscular dystrophy.
